Cyp1b1 exerts opposing effects on intestinal tumorigenesis via exogenous and endogenous substrates.
Cytochrome P450 1B1 (Cyp1b1) metabolism contributes to physiologic functions during embryogenesis but also to carcinogenic activation of polycyclic aromatic hydrocarbons (PAH). We generated Cyp1b1-deficient mice carrying the Min allele of the adenomatous polyposis coli gene. These Cyp1b1-deficient Min mice developed twice as many tumors as Min controls, which, however, remained similar in size and histology. Tumors from older (130 days) Cyp1b1-deficient Min mice selectively exhibited focal areas of nuclear atypia associated with less organized epithelia. The metabolism of endogenous substrates by Cyp1b1, therefore, suppresses tumor initiation but also affects progression. Treatment of Min mice with 7,12-dimethylbenzanthracene (DMBA) doubled both tumor multiplicity and size within 20 days but not when mice lacked Cyp1b1. This was paralleled by an abnormal staining of crypts with beta-catenin, phospho-IkappaB kinase, and RelA, which may represent an early stage of tumorigenesis similar to aberrant crypt formation. Cyp1b1 deletion did not affect circulating DMBA and metabolites. Cyp1b1 expression was higher in the tumors compared with normal small intestines. Increased tumorigenesis may, therefore, arise from generation of DMBA metabolites by Cyp1b1 in the developing tumors. Benzo(a)pyrene (BP), which is similarly activated by Cyp1b1 in vitro, did not affect tumorigenesis in Min mice. By contrast, BP and DMBA each suppressed tumor multiplicity in the absence of Cyp1b1. Cyp1b1 metabolism of DMBA and endogenous oxygenation products may each affect a tumor-promoting nuclear factor-kappaB activation, whereas Ah receptor activation by PAH affects suppression. Tumorigenesis may, therefore, depend on activation of PAH by Cyp1b1 and on offsetting suppression by Cyp1b1 of endogenous tumor-enhancing substrates.
Halberg
Richard B
RB
Department of Pharmacology, University of Wisconsin, Madison, Wisconsin 53706, USA.
Larsen
Michele Campaigne
MC
Elmergreen
Tammy L
TL
Ko
Alex Y
AY
Irving
Amy A
AA
Clipson
Linda
L
Jefcoate
Colin R
CR
D015127:9,10-Dimethyl-1,2-benzanthracene / Q000493:pharmacokinetics; D000818:Animals; D001189:Aryl Hydrocarbon Hydroxylases / Q000172:deficiency / Q000378:metabolism*; D001564:Benzo(a)pyrene / Q000493:pharmacokinetics; D002273:Carcinogens / Q000493:pharmacokinetics*; D065633:Cytochrome P-450 CYP1B1; D005260:Female; D051550:I-kappa B Kinase / Q000378:metabolism; D007414:Intestinal Neoplasms / Q000139:chemically induced / Q000201:enzymology* / Q000235:genetics; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D000069463:Olive Oil; D010766:Phosphorylation; D010938:Plant Oils / Q000493:pharmacokinetics; D051996:Transcription Factor RelA / Q000378:metabolism; D051176:beta Catenin / Q000378:metabolism
D002273:Carcinogens; D000069463:Olive Oil; D010938:Plant Oils; C498144:Rela protein, mouse; D051996:Transcription Factor RelA; D051176:beta Catenin; D001564:Benzo(a)pyrene; D015127:9,10-Dimethyl-1,2-benzanthracene; D001189:Aryl Hydrocarbon Hydroxylases; C585498:Cyp1b1 protein, mouse; D065633:Cytochrome P-450 CYP1B1; D051550:I-kappa B Kinase
Cell. 2004 Aug 6;118(3):285-96
15294155
Cancer Detect Prev. 2005;29(6):562-9
16289386
Cancer Res. 2003 Aug 15;63(16):4872-7
12941808
Anticancer Res. 2004 Sep-Oct;24(5A):2595-9
15517863
Nat Genet. 1997 Sep;17(1):88-91
9288104
Cell. 1990 Jun 1;61(5):759-67
2188735
Genome Biol. 2007;8(7):R131
17615082
Drug Metab Rev. 2006;38(1-2):337-52
16684663
Toxicol Appl Pharmacol. 2006 May 15;213(1):18-26
16226778
Free Radic Biol Med. 2008 Feb 15;44(4):570-83
17997381
Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):8977-81
8415640
Cancer Res. 2001 Dec 1;61(23):8435-40
11731424
Clin Cancer Res. 2005 May 15;11(10):3758-65
15897573
Cancer Res. 2006 Aug 1;66(15):7571-7
16885356
J Biol Chem. 1996 Nov 8;271(45):28324-30
8910454
Toxicol Appl Pharmacol. 2006 Nov 1;216(3):469-78
16893557
Oncogene. 2006 Dec 4;25(57):7512-21
17143295
Development. 2007 Apr;134(7):1369-83
17329364
Carcinogenesis. 2003 Feb;24(2):327-34
12584184
Cancer Res. 1995 Oct 1;55(19):4479-85
7671263
Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9769-73
15210940
J Biol Chem. 1994 May 27;269(21):14905-11
8195121
Carcinogenesis. 2005 Mar;26(3):587-95
15579483
Cancer Res. 1997 Jul 15;57(14):3026-31
9230218
Carcinogenesis. 2006 Jun;27(6):1204-13
16387742
Mol Cancer Res. 2006 Mar;4(3):135-50
16547151
J Cell Sci. 1996 Nov;109 ( Pt 11):2619-25
8937980
Nat Rev Immunol. 2005 Oct;5(10):749-59
16175180
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9530-5
12886021
J Immunol. 2008 Feb 15;180(4):2588-99
18250470
Cancer Res. 2006 Sep 15;66(18):9090-8
16982751
Proc Natl Acad Sci U S A. 2005 May 10;102(19):6960-5
15870186
Mutat Res. 1999 Jul 15;443(1-2):139-47
10415437
Science. 2003 Mar 7;299(5612):1578-81
12624268
J Immunol. 2007 Sep 1;179(5):2681-5
17709478
Am J Pathol. 2007 Mar;170(3):855-64
17322371
Genes Dev. 2004 Jun 15;18(12):1385-90
15198980
Toxicol Appl Pharmacol. 2005 Feb 1;202(3):244-57
15667830
Oncogene. 2004 Nov 25;23(55):8992-6
15480419
Cancer Metastasis Rev. 2007 Dec;26(3-4):503-24
17943411
Arch Biochem Biophys. 1997 Nov 15;347(2):181-92
9367523
Chem Res Toxicol. 2007 Mar;20(3):489-96
17291012
Stem Cell Rev. 2006;2(3):203-12
17625256
Mutat Res. 2006 Apr 30;604(1-2):60-70
16574467
Drug Metab Dispos. 2003 Nov;31(11):1346-51
14570766
J Clin Invest. 2007 Jul;117(7):1940-50
17607366
J Biol Chem. 1994 May 6;269(18):13092-9
8175734
Chem Res Toxicol. 2004 Dec;17(12):1667-74
15606143
Carcinogenesis. 2000 Aug;21(8):1567-72
10910960